secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001104659-25-069489
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune receives FDA Complete Response Letter for RP1 BLA in advanced melanoma
--------------------------------------------------------------------------------

- FDA issues CRL for RP1 + nivolumab; IGNYTE trial deemed not adequate/well-controlled.
- CRL cites heterogeneous patient population and need to address confirmatory trial design.
- No safety issues raised; Company requests Type A meeting within 30 days.
- CEO surprised as issues not raised during mid- or late-cycle reviews.
- Without accelerated approval, RP1 development for advanced melanoma patients not viable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925069489/0001104659-25-069489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925069489/tm2521403d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-069489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer